All In Biotech

Drug Trial Radar · NCT03830671

The Effect of 18-month Regimen Containing 6 Anti-tuberculosis Drugs for Patients With MDR-TB

The Effect of New MDR-TB Regimen With 18 Month Duration Containing 6 Anti-tuberculosis Drugs

Last checked: Nov 19, 2026Latest source record: Oct 12, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

515

Actual

Start

Mar 8, 2019

Primary completion

Jun 8, 2022

Study completion Jun 8, 2022

Sponsor

Lead sponsor
Beijing Chest HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 5, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

WHO has recommended that multidrug-resistant tuberculosis (MDR-TB, defined as resistance to at least isoniazid (H) and rifampicin (R) be addressed as a public health crisis and enhance capacity to deliver effective treatment and care. According to the 2018 WHO TB Report, the overall treatment success rate of MDR-TB is 55% while much lower in China at just only 41% with the 24-month regimen. In order to further verify the safety and efficiency of optimizing shorter 18-month regimen containing 6 anti-TB drugs with MDR-TB patients,500 more patients will be enrolled and observed.

Conditions

  • Multi-drug Resistant Tuberculosis

Interventions

  • 18-month regimen containing 6 anti-TB drugsDrug

    Investigational regimen:3Am-Mfx-PZA-X-Y-Z/3Am3-Mfx-PZA-X-Y-Z/12 Mfx-PZA-X-Y-Z.X、Y、Z are the drugs susceptible or possibly susceptible to mycobacterial bacilli(The candidated drugs to be selected are:Cs-Cycloserine,Pto-Protionamide,Clr-Clarithromycin,PAS-sodium para-aminosalicylate,E-ethambutol,Bdq-Bedaquiline,Cfz-Clofazimine,Lzd-linezolid).The abbreviation of the name of each drug in the regimen is explained as follows: PZA-pyrazinamide,Am-Amikacin,Mfx-moxifloxacin)and the total duration of the regimen is 18 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. the treatment success rateTime frame: at the end of treatment completion of all enrolled patients,an average of 18 months after the last patient enrolled
  2. death rateTime frame: at the end of treatment completion of all enrolled patients, an average of 18 months after the last patient enrolled

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Chest Hospital

    Beijing, China

  • The 8th Medical Center of Chinese Pla General Hospital

    Beijing, China

  • Changchun Infectious Disease Hospital

    Changchun, China

  • Hunan Institute For Tuberculosis Control

    Changsha, China

  • Public Health Clinical Center of Chengdu

    Chengdu, China

  • Shenzhen Third Peple's Hospital

    Guangzhou, China

  • Guangzhou Chest Hospital

    Guanzhou, China

  • The Affiliated Hospital of Guizhou Medical University

    Guiyang, China

  • Infectious Disease Prevention Hospital in Heilongjiang Province

    Harbin, China

  • Anhui Chest Hospital

    Hefei, China

  • The Fourth People's Hospital of Inner Mongolia Autonomous region

    Hohhot, China

  • Shandong Provincial Chest Hospital

    Jinan, China

  • Shanghai Pulmonary Hospital

    Shanghai, China

  • Shenyang Chest Hospital

    Shenyang, China

  • Tianjin Haihe Hospital

    Tianjin, China

  • Chest of Hospital of Xinjiang Uygur Autonomous Region of the PRC

    Ürümqi, China

  • The Tuberculosis Prevention and Treatment Hospital of Shanxi Province

    Xi'an, China

  • Xi'an Chest Hospital

    Xi'an, China

  • The Fourth People's Hospital of Ningxia Autonomous Region

    Yinchuan, China

  • The Infectious Disease Hospital of Wangkai Zaozhuang

    Zaozhuang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.